Skip Navigation

European Journal of Heart Failure 2002 4(6):707-712; doi:10.1016/S1388-9842(02)00168-X
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herrmann, S.-M.
Right arrow Articles by Regitz-Zagrosek, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, S.-M.
Right arrow Articles by Regitz-Zagrosek, V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 European Society of Cardiology

Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: the GLAECO and GLAOLD studies

Stefan-Martin Herrmanna,*, Viviane Nicaudb, Klaus Schmidt-Petersena, Jacqueline Pfeifera, Jeanette Erdmannc, Theresa McDonaghd, Henry J. Dargied, Martin Paula and Vera Regitz-Zagrosekc

a Institute of Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, Benjamin Franklin Medical Center, Freie Universität Berlin Hindenburgdamm 30, 12200 Berlin, Germany
b Inserm U525, Epidemiologic and Molecular Genetics of Cardiovascular Diseases Paris, France
c German Heart Institute, Humboldt University Berlin Berlin, Germany
d Department of Cardiology and MRC Clinical Research Initiative in Heart Failure, Western Infirmary and University of Glasgow Glasgow, UK

* Corresponding author. Tel.: +49-30-8445-2293; fax: 49-30-8445-4482. E-mail address: herrmann{at}medizin.fu-berlin.de


   Abstract

Background: The angiotensin II type 2 (AT2) receptor is thought to play a role in cardiovascular disorders such as neointima formation after vascular injury, cardiac hypertrophy and myocardial infarction (MI). Recently, the biallelic polymorphism G+1675A in intron 1 of the AT2 receptor gene has been associated with left ventricular posterior, septal and relative wall thickness, as well as left ventricular mass index in young hypertensive males.

Methods: To investigate its potential role in left ventricular hypertrophy (LVH) and other cardiovascular traits, 1968 individuals from two population samples (the Glasgow Heart Scan, GLAECO and Glasgow Heart Scan Old, GLAOLD studies) with echocardiographically and electrocardiographically assessed phenotypes, were genotyped for G+1675A using allele-specific oligonucleotide hybridization. Both studies had a similar design, only the age-ranges differed, being 25–74 years in the GLAECO study and 55–74 years in the GLAOLD study, so that internal consistency of results could also be assessed. Since the AT2 gene is located on the X chromosome, males and females were analysed separately.

Results: The +1675A allele frequency was 0.49 and 0.51, in the GLAECO and GLAOLD studies, respectively. In both studies, the genotype frequencies were similar in hypertensive and non-hypertensive individuals. In the GLAOLD study, in females with episodes of coronary ischemia and MI, the AT2 +1675A allele was more common than in females with no episode (86.5% vs. 73.5%, respectively; P<0.007). This effect was not observed in males. In the same study, AT2 +1675A allele carriers were more common in males with LVH, than in those without LVH (60.3% vs. 46.0%, respectively; P=0.047). This result was unchanged after exclusion of subjects taking antihypertensive drugs (including ACE inhibitors) (64.4% vs. 47.4%, P=0.038). However, in the GLAECO study, these results could not be replicated, even when subjects >55 years of age were considered separately.

Conclusions: Our study gives rise to a potential implication of the AT2 G+1675A polymorphism in LVH and coronary ischemia subgroups. Since these results were not consistent in both studies, but are partially in agreement with two independent investigations, further efforts should be made to elucidate the specific nature of these genotype/phenotype interactions.

Key Words: Angiotensin II type 2 receptor gene • Genetic polymorphism • Left ventricular hypertrophy • Coronary ischemia

Received September 26, 2001; Revised February 21, 2002; Accepted March 26, 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Warnecke, P. Mugrauer, D. Surder, J. Erdmann, C. Schubert, and V. Regitz-Zagrosek
Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1729 - R1735.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Alfakih, R. A. Lawrance, A. Maqbool, K. Walters, S. G. Ball, A. J. Balmforth, and A. S. Hall
The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease
Eur. Heart J., March 2, 2005; 26(6): 584 - 589.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Kuznetsova, J. A. Staessen, L. Thijs, C. Kunath, A. Olszanecka, A. Ryabikov, V. Tikhonoff, K. Stolarz, G. Bianchi, E. Casiglia, et al.
Left Ventricular Mass in Relation to Genetic Variation in Angiotensin II Receptors, Renin System Genes, and Sodium Excretion
Circulation, October 26, 2004; 110(17): 2644 - 2650.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Alfakih, A. Maqbool, M. Sivananthan, K. Walters, G. Bainbridge, J. Ridgway, A. J. Balmforth, and A. S. Hall
Left Ventricle Mass Index and the Common, Functional, X-Linked Angiotensin II Type-2 Receptor Gene Polymorphism (-1332 G/A) in Patients With Systemic Hypertension
Hypertension, June 1, 2004; 43(6): 1189 - 1194.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.